Prostate-specific membrane antigen (PSMA)-targeted and choline tracers used in prostate cancer imaging, and octreotide analogues that target the somatostatin receptor often overexpressed by neuro-endocrine tumours, were the most frequently reported. This evidence concerns the gene FOLH1 and Familial prostate cancer.